Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25, 2023 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
April 10, 2023 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
March 30, 2023 07:00 ET
|
Anavex Life Sciences Corp.
Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to ANAVEX®2-73...
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
March 09, 2023 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
February 07, 2023 07:00 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
February 02, 2023 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
January 31, 2023 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
December 14, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 12, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
December 02, 2022 16:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...